Skip to main content

Cart T cell therapy for multiply myeloma

EDM (Early Day Motion) 244: tabled on 04 July 2022

Tabled in the 2022-23 session.

This motion has been signed by 4 Members. It has not yet had any amendments submitted.

Motion text

That this House notes and recognises the impact multiply myeloma has on one's life; further notes that this particular blood cancer develops in the bone marrow called plasma cells and impacts the immune system; highlights the importance of Chimeric Antigen Receptor T Cell Therapy, better known as Cart T Cell Therapy, which has been approved to treat Lymphomas; further highlights that this treatment was approved by the Department of Health Cancer Strategy the NICE for the end of 2021, but has not yet been implemented for use in Northern Ireland; notes how this certain therapy could alter and save the lives of so many individuals suffering with MM; further notes the situation of my constituent who is waiting this type of treatment for MM and is currently being overlooked as this is not available for use yet in Northern Ireland, but is already in use in the mainland; and calls for the Department of Health and Social Care to undertake discussion with the relevant Minister in Northern Ireland to ensure that this treatment is available in Northern Ireland as soon as possible.

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.

There are no withdrawn signatures for this motion.